Bellevue Life Sciences Acquisition Corp. Rights
BLACR
BLACR was delisted on the 14th of February, 2025.
22 hedge funds and large institutions have $833K invested in Bellevue Life Sciences Acquisition Corp. Rights in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
74% more capital invested
Capital invested by funds: $479K → $833K (+$355K)
57% more funds holding
Funds holding: 14 → 22 (+8)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASM
ATW SPAC Management
New York
|
+$54.2K |
| 2 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$43.5K |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$43.5K |
| 4 |
ETH
Exos TFP Holdings
New York
|
+$34.8K |
| 5 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
+$34.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
-$28.9K |
| 2 |
CAC
Cowen and Company
New York
|
-$22.5K |
| 3 |
SOA
Sea Otter Advisors
Miami,
Florida
|
-$3.99K |
| 4 |
BI
Bulldog Investors
Saddle Brook,
New Jersey
|
-$356 |
BLACR Hedge Fund Activity: Q2 2023 in Review
22 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q2 2023, worth a combined $833K — up 74% from $479K a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new BLACR positions and 2 closed out — a net gain of 8 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was ATW SPAC Management, opening a new position worth an estimated $54.2K. The largest seller was Oaktree Capital Management, exiting entirely with an estimated $28.9K sold.
- 22 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q2 2023, up from 14 in Q1 2023.
- Funds reported $833K of Bellevue Life Sciences Acquisition Corp. Rights stock for Q2 2023, up 74% quarter-over-quarter.
- 10 funds opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q2 2023 and 2 closed out, a net change of +8 holders.
- The largest Bellevue Life Sciences Acquisition Corp. Rights buyer in Q2 2023 was ATW SPAC Management, an estimated $54.2K added.
- The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q2 2023 was Oaktree Capital Management, an estimated $28.9K sold.
Based on aggregated 13F filings for Q2 2023.